All In Biotech

Drug Trial Radar · NCT02274233

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia

Last checked: Nov 19, 2026Latest source record: Sep 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

24

Actual

Start

Oct 2014

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Sideris PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety and amount of the study drug in the blood after increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.

Conditions

  • Iron Overload
  • Beta-Thalassemia

Interventions

  • SP-420Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Up to 35 days

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Sideris Investigative Site

    Boston, Massachusetts

  • Sideris Investigative Site

    New York, New York

  • Sideris Investigative Site

    Philadelphia, Pennsylvania

  • Sideris Investigative Site

    Toronto, Ontario, Canada

  • Sideris Investigative Site

    Beirut, Lebanon

  • Sideris Investigative Site

    Bangkok, Thailand

  • Sideris Investigative Site

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.